New drug could change kidney transplants forever

NCT ID NCT07290777

Not yet recruiting Disease control Sponsor: Veloxis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called VEL-101 in 120 kidney transplant patients. The goal is to see if VEL-101 can safely replace the standard drug tacrolimus, which often causes side effects. Researchers will monitor for rejection, side effects, and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VEL-101 (also called Pegrizeprument or FR104)
What this could lead to: If successful, VEL-101 could offer kidney transplant patients a new option that may have fewer side effects than current standard drugs like tacrolimus.
What could go wrong: This is an early phase 2 trial with only 120 participants, so results are preliminary. The drug may not prove safer or more effective than existing treatments, and there is a risk of rejection or serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSPLANTATION, KIDNEY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.